Orchid Chemicals And Pharmaceuticals
Orchid Chemicals and Pharmaceuticals Ltd., commonly referred to as Orchid Pharma, is a prominent player in the Indian pharmaceutical industry, headquartered in Chennai, India. Founded in 1992, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms, particularly in the areas of anti-infectives, cardiovascular, and central nervous system medications. With a strong presence in both domestic and international markets, Orchid Pharma has achieved significant milestones, including regulatory approvals from major global health authorities. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic segments. Orchid's strategic focus on research and development has positioned it as a competitive force in the pharmaceutical landscape, making it a trusted partner for healthcare providers worldwide.
DitchCarbon Score
How does Orchid Chemicals And Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orchid Chemicals And Pharmaceuticals's score of 31 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orchid Chemicals And Pharmaceuticals's reported carbon emissions
In 2023, Orchid Chemicals and Pharmaceuticals reported significant carbon emissions, totalling approximately 459,400 kg CO2e for Scope 1 and about 381,028,000 kg CO2e for Scope 2. This indicates a substantial operational footprint, particularly in Scope 2 emissions, which are primarily associated with electricity consumption. For the previous year, 2024, the company demonstrated a notable reduction in emissions, with Scope 1 emissions decreasing to about 339,939 kg CO2e and Scope 2 emissions at approximately 41,557,479 kg CO2e. This reduction reflects a commitment to improving energy efficiency and reducing reliance on fossil fuels. Orchid Pharma has set long-term climate commitments, aiming for net-zero emissions across all scopes by 2050. This commitment was formalised in 2024, aligning with the Science Based Targets initiative (SBTi) framework. The company is actively working towards these targets, indicating a proactive approach to climate change mitigation within the pharmaceuticals sector. Overall, Orchid Chemicals and Pharmaceuticals is making strides in reducing its carbon footprint while committing to ambitious long-term climate goals, positioning itself as a responsible player in the industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 4,594,000 | 000,000.00 |
| Scope 2 | 381,028,000 | 00,000,000.00 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orchid Chemicals And Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
